Conclusions Are Not Supported by the Published Statistical Analysis. Comment on López-Toledo et al. Flaxseed Improves Glucose and Lipid Metabolism in Mexican Subjects with Type 2 Diabetes: A Parallel Randomized Clinical Trial. Nutrients 2025, 17, 709
Robert W. Spitz, Deependra K. Thapa, Thirupathi Reddy Mokalla, Wasiuddin Najam, Andrew W. Brown, David B. Allison

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
- —National Institutes of Health
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPhytoestrogen effects and research · Diet, Metabolism, and Disease · Nutritional Studies and Diet
López-Toledo et al. conducted an interesting randomized, parallel-group clinical trial comparing the effects of flaxseed powder on various biochemical markers in adult patients with uncontrolled Type 2 diabetes who are currently taking metformin [1]. If correct, the authors’ data suggest that three months of consuming 16 g of flaxseed per day decreased glucose, total cholesterol, and triglyceride levels [1]. This suggests that flaxseed consumption has an important role in preventing or mitigating disorders of lipid metabolism and glucose disposal. While the results seem promising, these conclusions are not supported by the published analyses because they are based on within-group comparisons rather than between-group tests of statistical significance [2,3].
A Difference in Nominal Significance (DINS) error occurs when within-group analyses are used to draw conclusions about between-group differences, without directly comparing groups [4,5]. Stated simply, a statistically significant change from the baseline measurement (p < 0.05) was observed in the intervention group, but not in the control group (p > 0.05). The article authors then concluded that the intervention changed more than the control without directly comparing the changes. This approach can inflate the type one error rate of 0.05 to as high as 50 percent [2,3,4] with equal sample sizes per group and asymptotically up to 95% when sample sizes are unequal. A more robust approach to compare between group changes would involve the use of an ANCOVA, with the baseline values serving as the covariate [6]. ANCOVA typically has the highest statistical power for comparing changes from baseline [6].
The registered primary outcomes are presented in two separate figures stratified by experimental condition with insufficient detail to estimate effects. These figures depict identical point estimates in the control group and intervention group, which would result in a p-value of 1 for between group comparisons. We contacted the authors several times and requested the raw data so that we could test the reproducibility and evaluate the verifiability of their analyses. After submitting our initial draft of this letter to the editor, the authors provided us with the raw data and the results of their new analysis following our recommendations. We were able to replicate their new results. While, their new results, align with their original conclusions, it is still important to underscore the importance of directly comparing groups to avoid potential DINS errors in the future.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1López-Toledo S. Pineda De la Cruz M.C. Gutiérrez-Hurtado I.A. Gijón-Soriano A.L. Martinez-Martínez E. Valencia-Santiago C. Orellana-Centeno J.E. Ramírez-García S.A. Pacheco-Cruz R. Flaxseed Improves Glucose and Lipid Metabolism in Mexican Subjects with Type 2 Diabetes: A Parallel Randomized Clinical Trial Nutrients 20251770910.3390/nu 1704070940005038 PMC 11858396 · doi ↗ · pubmed ↗
- 2Bland J.M. Altman D.G. Comparisons against baseline within randomised groups are often used and can be highly misleading Trials 20111226410.1186/1745-6215-12-26422192231 PMC 3286439 · doi ↗ · pubmed ↗
- 3Bland J.M. Altman D.G. Best (but oft forgotten) practices: Testing for treatment effects in randomized trials by separate analyses of changes from baseline in each group is a misleading approach Am. J. Clin. Nutr.201510299199410.3945/ajcn.115.11976826354536 · doi ↗ · pubmed ↗
- 4Gelman A. Stern H. The difference between “significant” and “not significant” is not itself statistically significant Am. Stat.20066032833110.1198/000313006 X 152649 · doi ↗
- 5Allison D.B. Brown A.W. George B.J. Kaiser K.A. Reproducibility: A tragedy of errors Nature 2016530272910.1038/530027 a 26842041 PMC 4831566 · doi ↗ · pubmed ↗
- 6Vickers A.J. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: A simulation study BMC Med. Res. Methodol.20011610.1186/1471-2288-1-611459516 PMC 34605 · doi ↗ · pubmed ↗
